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Can Ex Vivo Magnetic Resonance Imaging of Rectal Cancer
Specimens Improve the Mesorectal Lymph Node Yield for
Pathological Examination?
Rutger Stijns, MD,*† Bart Philips, MD,* Carla Wauters, MD, PhD,‡ Johannes de Wilt, MD, PhD,†
Iris Nagtegaal, MD, PhD,§ and Tom Scheenen, PhD*
Purpose: The aim of this study was to use 7 Tex vivo magnetic resonance imag-
ing (MRI) scans to determine the size of lymph nodes (LNs) in total mesorectal
excision (TME) specimens and to increase the pathological yield of LNs with
MR-guided pathology.
Materials andMethods: Twenty-two fixated TME specimens containing adeno-
carcinoma were scanned on a 7 T preclinical MRI system with a T1-weighted
3-dimensional gradient echo sequencewith frequency-selective lipid excitation (repe-
tition time/echo time, 15/3 milliseconds; resolution, 0.293 mm3) and a water-excited
3-dimensional multigradient echo (repetition time, 30 milliseconds; computed echo
time, 6.2 milliseconds; resolution, 0.293 mm3) pulse sequence.
The first series of 11 TME specimens (S1) revealed the number and size
of LNs on both ex vivo MRI and histopathology. The second series of 11 TME
specimens (S2) was used to perform MR-guided pathology. The number, size,
and percentages of yielded LNs of S1 and S2 were compared.
Results: In all specimens (22/22), a median number of 34 LNs (interquartile
range, 26–34) was revealed on ex vivo MRI compared with 14 LNs (interquartile
range, 7.5–21.5) on histopathology (P = 0.003). Mean size of all LNs did not dif-
fer between the 2 series (ex vivo MRI: 2.4 vs 2.5 mm, P = 0.267; pathology:
3.6 vs 3.5 mm, P = 0.653). The median percentages of harvested LNs compared
with nodes visible on ex vivo MRI per specimen for both series were not signif-
icantly different (40% vs 43%, P = 0.718). By using a size threshold of greater
than 2 mm, the percentage improved to 71% (S1) and to 78% (S2, P = 0.895).
The median number of harvested LNs per specimen did not increase by perform-
ing MR-guided pathology (S1, 14 LNs; S2, 20 LNs; P = 0.532).
Conclusions: Ex vivo MRI visualizes more LNs than (MR-guided) pathology is
able to harvest. Current pathological examination was not further improved byMR
guidance. The majority of LNs or LN-like structures visible on ex vivo MRI below
2 mm in size remain unexplained, which warrants a 3-dimensional approach for
pathological reconstruction of specimens.
Key Words: rectal cancer, magnetic resonance imaging, lymph node,
pathology, yield
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T he presence of lymph node (LN)metastases determines the treatmentregimen in rectal cancer patients. Magnetic resonance imaging
(MRI) is known to be the superior 3-dimensional imaging modality to
identify and characterize the tumor aswell as LNs in vivowith a high spa-
tial resolution.1 T2-weighed fast-spin echo sequences in particular enable
detailed visualization of the anatomy of the pelvis. Lymph nodes that are
likely to be involved in rectal cancer are located in the mesorectum. The
fatty tissue surrounding the rectum with an outer border defined as the
mesorectal fascia, which forms an important anatomical barrier for tumor
spread.Metastatic LNs are a strong risk factor for local recurrence and for
(disease-free) survival, also after curative treatment.2 The cornerstone of
curative treatment of the disease is resection according to the principle of
a total mesorectal excision (TME).3 Neoaduvant (chemo)radiotherapy is
given before surgery in case of suspected LN metastases or in case of lo-
cally advanced disease on clinical MRI.4
The approach for surgical resection in TME surgery depends on
the height of the lower pole of the tumor to the anorectal junction.5
Proximal or middle rectal tumors are treated with an anterior resection
and distal rectal tumors with an abdominoperineal excision.6–10
Both approaches have significant morbidity and can result in an im-
paired quality of life.11,12 The current clinical histopathological
evaluation of TME specimens focuses on tumor staging according
to the TNM criteria of the American Joint Cancer Committee.4,13 Next
to assessing the extent of the primary tumor, LNs are detected by inspec-
tion and palpation of thin axial tissue slices. International guidelines pre-
scribe a minimum pathological yield of 12 LNs.14–16 National guidelines
may deviate from this, such as in the Netherlands where 10 evaluated
LNs are considered to be sufficient.17 There are many factors that can
influence LN yield such as age, surgery, systemic diseases, and preop-
erative treatment.18,19 Especially preoperative treatment in the form of
(chemo)radiotherapy can lead to a reduced LN yield potentially leading
to understaging.18,20 High-quality pathological assessment of a TME
specimen is therefore crucial.
Multiple studies have aimed to improve LN yield of pathological
evaluation investigating LNmarkers, such as methylene blue staining.21–24
Until now, no research focused on the use of ex vivo MRI to visualize
LNs in a TME specimen. Clinical MR systems for in vivo staging of
the disease normally have amagnetic field-strength of 1.5 or 3 T. Surgical
specimens can be examined with preclinical MR systems with a smaller
magnet bore size, higher magnetic field strength, and stronger magnetic
field gradients. By applying dedicated ex vivo MRI to rectal specimens,
3-dimensional imaging at a high spatial resolution can be obtained with
visualization of all LNs present in a rectal specimen.25 Subsequently,
these images can be used to guide the pathologist toward the visible LNs
during pathological workup.
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In this study, we developed a protocol for the use of 7 T ex vivo
MRI scans of TME specimens to determine the number and size of
mesorectal LNs thereby aiming to increase the pathological LN harvest
after MR-guided pathology.
METHODS
Design and Eligibility
A prospective, observational study to evaluate 2 series of rectal
cancer specimens was conducted in 2 referral centers for rectal cancer
treatment. The first series of rectal specimens (S1) was examined to es-
tablish the number and size of LNs separately on ex vivo MRI and on
standard histopathology. Histopathology of the first series was per-
formed in a standard workup with normal duration by pathologists un-
aware of this study. Lymph nodes detected on ex vivo MRI of the
second series (S2) were used to guide the pathologist during pathologic
examination of the specimen. Pathological workup for S2 was an exten-
sive search with a maximum of 2 hours. The number, size, and percent-
ages of yielded LNs of S1 and S2 were then compared. The number of
LNs visible on clinical in vivo T2-weightedMRI scans was also assessed
(repetition time [TR] and echo time [TE] of 3680–4980 milliseconds and
93–95 milliseconds; resolution, 0.5 0.5 3.0 mm3). The study design
is illustrated in Supplemental Figure 1, Supplemental Digital Content 1,
http://links.lww.com/RLI/A440. This study was approved by the institu-
tional review board of the medical ethical research committee of the
Radboud University Medical Centre with a waiver of informed consent
(registration number 2016–2490).
Patients
Twenty-two surgical specimens from patients with biopsy-proven
rectal cancer who were treated with a total mesenteric excision were in-
cluded in the study. The admission of neoadjuvant treatment according
to Dutch clinical guidelines—short-course radiotherapy or long-course
chemoradiotherapy—was no exclusion criterion.
Ex Vivo Magnetic Resonance Imaging
Magnetic resonance imaging of fixated rectal cancer specimens
was performed on a horizontal 7 T preclinical MR system (ClinScan;
Bruker BioSpin, Ettlingen, Germany) using a volume coil. Next to a
localizer, the MR protocol consisted of 2 parts: one part focused on im-
aging lipids, and the other part focusing on imaging of water, similar to
in vivo MRI of LNs at ultrahigh field strength.26 Magnetic resonance
imaging of lipids was performed with a T1-weighted 3-dimensional
gradient echo (GRE) sequence with frequency-selective lipid excitation
at a high isotropic spatial resolution of 0.29 0.29 0.29mm3 TR and
TE of 15 and 3 milliseconds, and excitation flip angle of 10 degrees.
Magnetic resonance imaging of water consisted of a 3-dimensional
multi-GRE pulse sequence of 5 acquired echoes and frequency-
selectivewater excitation at the same spatial resolution (TR, 30millisec-
onds; multiple TEs of 3.0, 7.6, 12.1, 16.6, 21.2 milliseconds, combined
into one computed TE image of 6.2 milliseconds; excitation flip angle
of 14 degrees).26 All TME specimens were of a size larger than 10 cm
and were scanned in multiple sections. These were merged to one com-
posed lipid and one inherently coregistered water 3-dimensional MR
image dataset.
To evaluate the ex vivo MR images, annotations were drawn
around the LNs on composed lipid and water-selective GRE images.
Two datasets were used simultaneously in search of spherical structures
suggested to be an LN. An LN, or an LN-like structure, was defined as a
spherical structure visible in 3 dimensions with low signal intensity on
lipid and high signal intensity on water-selective GRE images, respec-
tively. The assessment and differentiation between small blood vessels
and LNs was performed by simultaneously evaluating transverse, sagit-
tal, and coronal cross-sections through the datasets. All ex vivoMR im-
ages were evaluated by a trained researcher to assess the number and
size of LNs or LN-like structures present in the TME specimen. The
reader was able to make thin maximum intensity projections.
MR-Guided Pathology
Lymph nodes detectable on ex vivo MRI of S2 were annotated
using the software package MeVisLab (MeVis Medical Solutions,
FIGURE 1. Example of a 3-dimensional dataset (A, coronal plane; B, sagittal plane; C and D, axial plane) of water- and lipid- (left, right) selective
imaging that was used to guide the pathologist toward structures as annotated with the yellow circles and numbers in the different images.
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Fraunhofer MEVIS). The annotations were shown to the pathologist
during the macroscopic specimen examination. The trained researcher
who evaluated the ex vivo MR images was present during the specimen
examination and provided a laptop with MR datasets with annotated
structures to provide navigation during pathology. Every spherical
structure in 3 dimensions detected on MRI was supposed to be har-
vested. The pathologist and trained researcher used the MR images
and annotations together to locate and yield LN-like structures present
in the surgical specimen. Conventional pathological examination (S1)
took approximately 30minutes per specimen to stage the primary tumor
and harvest the LNs. A timeslot of 120 minutes was reserved for
MR-guided pathological evaluation (S2) per TME specimen.
Histopathological Preparation and Diagnosis
All specimens were fixated in 10% buffered formalin for at least
48 hours before ex vivo MRI. Macroscopic evaluation was done by slic-
ing the specimen from the distal resection margin to the proximal margin
in serial transverse tissue lamina at a 5-mm interval. Each transverse tis-
sue slice was evaluated by inspection, palpation, and perpendicular slic-
ing. Detected LNs or fatty tissue thought to contain LNs were then
embedded in paraffin. Subsequently, sections of 4-μm thickness were
sliced from each embedded paraffin tissue block, mounted on glass slides
(6  2 cm), and stained with hematoxylin-eosin. In case of absence of
LNs during microscopy, multiple cross-sections of the paraffin-
embedded tissue block were prepared to verify the presence of LNs. In
addition, D2-40 and CD34 immunohistochemistry was performed on a
selection of fragments to expose lymphatic and/or vascular structures.27
Statistical Analysis
The LN harvest by using MR-guided pathology compared with
standard pathologic workup was evaluated. Baseline characteristics of
the included patients were compared using the unpaired t test. The me-
dian number of LNs examined in both series was calculated for explan-
atory variables across all stages. The number, size, and percentages of
FIGURE 2. Rectal specimen (A) that was examined using MR-guided pathology to harvest the smallest lymph nodes. In this specimen, separate
tissue samples were scanned individually and used for guidance (B–D). A small lymph node of 2 mm on MRI (E, red circle) and on pathology (F) was
detected with this specific MR-guided pathology approach.
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detected LNs of the 2 series were compared. T tests, χ2 tests, and
Mann-Whitney U tests were used to determine the statistical signifi-
cance of differences for ordinal and categorical variables, respectively.
A P value of less than 0.05 was considered to be statistically significant.
The data were analyzed with the SPSS Statistics V22.0 (SPSS Inc, Chicago,
IL). Sizes and frequencies were additionally displayed in histograms
made with Graphpad Prism 5.03 (GraphPad Software, Inc).
RESULTS
Twenty-two TME specimens with biopsy-proven adenocarci-
noma of the rectum were included in the study. All 22 specimens were
successfully scanned with our protocol designed for ex vivo 7 T lipid and
water-selective MRI. The composed lipid and water-selective datasets
were used for the detection of round-shaped structures, and all structures
visible could be evaluated in 3 dimensions. An example of the
3-dimensional MR datasets is displayed in Figures 1 and 2. Relevant
patient-related baseline and pathology characteristics did not reveal sig-
nificant differences, except for the mean age (Table 1).
In general, more LN-like structures were discovered on MRI
than LNs were harvested during pathological examination. On clinical
in vivo MR images, a median number of 14 LNs for S1 (interquartile
range [IQR], 8–16) and 12 LNs for S2 (IQR, 8–16) were visible, with-
out statistical significant difference (P = 0.899). Overall, a median num-
ber of 34 (IQR, 26–43) and 14 (IQR, 7.5—21.5) LNs per specimen
were revealed on ex vivo MRI and histopathology, respectively. This
median difference in yield was significant for both series (S1,
P = 0.003; S2, P = 0.004, calculated with Mann-Whitney U test). For
each individual specimen, the total number of LNs or LN-like structures
that was detected on ex vivoMRI was the largest over in vivo or histopath-
ologically detected nodes (Fig. 3, A and B). Numbers and size for detected
LNs on ex vivo MRI and during pathological examination for both series
are presented in Table 2. The mean size of all LNs did not differ between
the 2 series (ex vivo MRI: 2.4 mm vs 2.5 mm, P = 0.267; pathology:
3.6 mm vs 3.5 mm, P = 0.653; calculated with 1-sample t test). The ad-
mission of neoadjuvant chemoradiotherapy did not lead to a mean size
difference between harvested LNs. The size distribution of harvested
LNs appeared similar between the 2 series (Fig. 4). Final pathological
assessment showed no differences between both series for the median
number of LNs harvested during pathological examination (14 LNs
for S1, range 4–30; and 20 LNs for S2, range 5–29; P = 0.532).
Ratios of LN yield compared with the number of LNs detected
on ex vivo MRI were calculated to provide further insight in the poten-
tial benefit ofMR-guided pathology. Amedian 40% (range, 13%–95%)
of the nodes visible on ex vivo MRI were pathologically harvested for
S1 and 43% (range, 27%–73%) for S2. By using a size threshold for
nodes larger than 2 mm, the median percentage of harvested LNs im-
proved to 71% (range, 20%–150%) and 78% (range, 38%–250%) for
S1 and S2, respectively. Statistical significance was tested by using
the Mann-Whitney U test.
The paraffin-embedded tissue blocks of 34 tissue fragments in
which initially no LNs were found were cross-sectioned multiple times.
This subanalysis revealed 2 additional LNs (an example is illustrated in
Supplemental Fig. 2, Supplemental Digital Content 2, http://links.lww.
com/RLI/A441). The cross-sections of the 32 other tissue blocks re-
vealed nerve branches and blood vessels. The D2-40 and CD34 immu-
nohistochemistry was also performed on these tissue samples. The
immunohistochemical analysis using D2-40 and CD34 did not expose
any additional lymphatic structures in these fragments.
DISCUSSION
In this work, we evaluated the use of ultrahigh field MRI of surgical
TME specimens to guide pathology for extensive LN staging. OurMR pro-
tocol enabled obtaining isotropic, high spatial resolution images of good
quality. This 3-dimensional MR visualization of a surgical specimen is, to
TABLE 1. Baseline Characteristics and Findings for Standard and Magnetic Resonance–Guided Pathology for Patients Assigned to S1 or S2
Series 1 (n = 11) Series 2 (n = 11) P
Mean age, y 62 68 0.024 (t test)
Sex
Male 5 9 0.076 (χ2)
Female 6 2
Neoadjuvant treatment
None 5 6 0.540 (χ2)
Short-course radiotherapy 3 1
Chemoradiotherapy 3 4
Surgery
Low anterior resection 8 5 0.193 (χ2)
Abdominoperieal excision 3 6
Pathological T stage
pT0 1 2 0.316 (χ2)
pT1 1 4
pT2 3 1
pT3 6 4
pT4 0 0
Pathological N stage
pN0 6 8 0.319 (χ2)
pN1 3 3
pN2 2 0
Malignant nodes (median) 1.0 (0–7) 0.0 (0–2) 0.284 (Mann-Whitney U test)
Total nodes (median) 14.0 (4–30) 20.0 (5–29) 0.532 (Mann-Whitney U test)
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our knowledge, a novel approach to interpret and use ex vivo ultrahigh field
MRI for pathological support. By performing lipid and water-selective
imaging on a specimen that consists of a substantial proportion of lipid
tissue, LNs, and blood vessels, recognition of LNs or small water-
containing spherical structures could be done in a straightforward way.
Unfortunately, the current study did not show an effect of MR
guidance on the number and size of LN harvested from a rectal speci-
men. A remarkable finding was that ex vivo MRI visualized signifi-
cantly more and significantly smaller LNs than those yielded during
pathological examination. Even with additional effort consisting of
multiple sectioning and immunohistochemistry of excised tissue frag-
ments, an increased pathological LN yield could not be verified. No
histological substrate was detected for small structures that were clearly
visible on ex vivo MRI, which leaves us in nescience on the exact anat-
omy of these radiological structures. The hypothesis that these LN-like
structures could be found using MR-guided pathology was not con-
firmed. The question arises what those less than 2 mm MR structures
could be, apart from LNs. It could be that these structures are LNs,
but are missed during pathological evaluation. If not seen or palpated,
it is challenging to incorporate the correct corresponding tissue frag-
ments for further histological workup. Moreover, in 4 patients, minor
differences between the number of LNs on ex vivo MRI and pathology
were seen, without any specimen- or scanning-specific explanation for
this observation. These specimens did show a relatively large proportion
FIGURE 3. Number of lymph nodes per specimen found on in vivo and ex vivo MRI and pathology for (A) series 1 and for (B) series 2. Asterisk
marks patients treated with neoadjuvant chemoradiotherapy.
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of LNs larger than 2mm on ex vivoMRI (59%–88%), which are theoret-
ically easier to find during pathological evaluation.
Multiple microscopic cross-sections of tissue fragments not im-
mediately revealing LNs that were visible on ex vivoMRI revealed vas-
cular structures, nerve branches, or only lipid tissue on microscopic
evaluation. On a simultaneous evaluation of transverse, sagittal, and
coronal MR images, these representations of tubular structures such
as vessels and nerves can be easily differentiated from the appearance
of LNs. The 3-dimensional visualization with high spatial resolution
makes it unlikely to mistake LNs for tubular structures. The application
ofMR-guided pathology can be suffering from a learning curve, as a re-
sult of which the effect of MR-controlled pathology is not yet visible. It
seems plausible that the translation from a 3-dimensional MR dataset
(Supplementary Fig. 3, Supplemental Digital Content 3, http://links.
lww.com/RLI/A442) to a 2-dimensional approach such as current path-
ological evaluation is even more challenging than presumed, which
might have resulted in missing LNs below a certain size. Perhaps, a
3-dimensional pathological approach of TME specimens may improve
the anatomical correlation of 3-dimensional MRI with pathology.
Optimizing pathologic LN staging and LN yield has previously
been investigated. Zhang et al28 aimed to predict the presence of LN
metastases by evaluating chemical shift effects on ex vivo images with
promising results. Although the prediction of the LN status was not in-
vestigated in the current study, a combination of in vivo and ex vivo ul-
trahigh field MRI and LN prediction would be interesting.26,29 Recent
literature regarding pathological improvements mainly focused on the
postoperative use of methylene blue staining.21,22,24,30–33 Methylene
blue injection into the superior rectal artery significantly increased the
mean number of LN harvest in rectal cancer patients treated by TME
surgery with and without neoadjuvant chemoradiotherapy. Also LN re-
vealing solutions such as GEWF (glacial acetic acid, ethanol, water and
formalin) and acetone have been investigated to enhance the total LN
retrieval from rectal specimens.34 Not only larger but also smaller
LNs were retrieved using these solutions. However, not only the quan-
tity of evidence is limited, but also usage of these solutions involves
health risks for people working with these substances. Thus, although
these pathology preparations identify the presence of more and smaller
nodes, they are not widely integrated in standard pathological workup.
The accuracy for the prediction of involved mesorectal LNs using
MRI in vivo is approximately 75% to 80%.1 Morphological features such
as irregular border, signal heterogeneity, and a round shape combined with
size is the best predictor of nodal involvement, but is subject to interreader
variability, and accuracy drops significantly for small LNs.35 There is in-
creasing evidence that small LNs (≤3mm) can contain tumormetastases.25
Wang et al36 described a series of 31 rectal specimens that were examined
for patterns of tumor spread and metastasis. One hundred twenty-eight of
972 examined LNs in this study contained tumor metastases, of which
approximately 93% of the metastatic nodes were of a size 0.5 to 5 mm.
Märkl et al37 showed that in colon cancer, where neoadjuvant treatment
has no role, LN metastases were discovered in nodes with a size of 1 to
5 mm. These results imply that the detection of small LNs in rectal can-
cer is also relevant to prevent pathological understaging, especially be-
cause neoadjuvant (chemo)radiotherapy is thought to further reduce the
number and size of LNs.18
The mean number of LNs examined in literature varies from 14
to 20 nodes per specimen, which is in line with current international
standards.33,38–40 Variations between pathology laboratories are known
regarding the number of LNs that are evaluated in rectal cancer. This vari-
ety may be dependent on the biology of the tumor, but is also related to the
effort of the surgical and pathology team.41,42 Academic and teaching hos-
pitalswith different resources andworkload are thought to produce and ex-
amine a larger number of LNs.43–45 The current study was performed in
academic and/or teaching centers for rectal cancer treatment. This might
explain why LN yield did not increase by the additional MR guidance.
On the other hand, it can be stated that current standard pathologicTA
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examination is sufficient in harvesting the number of LNs as subscribed
by international guidelines.4
This study has some limitations. First, the study cohort of
22 specimens may not be large enough to prove a significant difference
in median LN harvest between the 2 approaches. Second, a large pro-
portion of the ex vivo MRI annotated LNs could not be detected during
pathology. Although we were able to obtain high-quality lipid and
water-selective MRI, which enabled a more or less straightforward rec-
ognition of LN-like structures in 3 dimensions, the question whether all
these structures are indeed LNs remained unanswered. A 3-dimensional
pathological analysis of the whole specimens could provide further in-
sight in future studies.
CONCLUSIONS
In conclusion, ex vivo 7 T MRI at a high spatial resolution visu-
alized structures that were challenging to harvest during (MR-guided)
pathology. The current study design with MR guidance was not able
to further improve standard pathological workup to increase the LN
yield. The histological origin of the majority of spherical structures be-
low 2 mm in size on MRI remained unconfirmed, which warrants a
3-dimensional approach for pathological reconstruction of specimens.
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